Masanari Mizuta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Masanari Mizuta has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
C. Chun‐Ping
Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Miyazaki Medical College, University of Miyazaki, Kiyotake, Miyazaki, Japan
1 shared publicationH. Ueno
Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Miyazaki Medical College, University of Miyazaki, Kiyotake, Miyazaki, Japan
1 shared publication- Hiroaki Ueno
Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan
1 shared publication K. Noma
Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Miyazaki Medical College, University of Miyazaki, Kiyotake, Miyazaki, Japan
1 shared publicationM. Nakazato
Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Miyazaki Medical College, University of Miyazaki, Kiyotake, Miyazaki, Japan
1 shared publicationMasamitsu Nakazato
Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki 889-1692, Japan
1 shared publication
Latest Publications
- 28 June 2008
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 10 (7) , 564-573
Pioglitazone attenuates fatty acid–induced oxidative stress and apoptosis in pancreatic β‐cells
Aims: Thiazolidinediones (TZDs), ligands for peroxisome proliferator–activated receptor γ, are antidiabetic agents that improve hyperglycemia by decreasing insulin resistance in obese diabetic animal models and patients with type 2 diabetes. We have studied whether pioglitazone, a TZD, can exert a direct effect against pancreatic β‐cell lipoapoptosis. Methods: MIN6 cells were cultured in medium containing either 5.6 (low glucose) or 25 mM glucose (high glucose) in the presence or absence of 0.5 mM palmitate for 48 h. We examined the effect of 10 μM pioglitazone on MIN6 cells on glucose‐stimulated insulin secretion, cellular ATP, uncoupling protein‐2 (UCP‐2) mRNA expression, intracellular triglyceride content, reactive oxygen species production, the number of apoptotic cells and nuclear factor‐κB (NF‐κB) activity. Results: Pioglitazone recovered partly impaired glucose‐stimulated insulin secretion and cellular ATP in MIN6 cell exposed to high glucose with 0.5 mM palmitate. Pioglitazone suppressed intracellular triglyceride accumulation in cells exposed to high glucose with 0.5 mM palmitate. Palmitate‐induced upregulation of UCP‐2 mRNA levels was suppressed by pioglitazone in a dose‐dependent manner. Pioglitazone decreased palmitate‐induced reactive oxygen species production in MIN6 cells by 24% and in mouse islet cells by 53%. Pioglitazone also decreased palmitate‐induced NF‐κB activity by 40% and protected β‐cells from palmitate‐induced apoptosis by 22% in MIN6 cell. Conclusions: Pioglitazone attenuated fatty acid–induced oxidative stress and apoptosis in pancreatic β‐cells. TZDs might be used as a mean for maintaining β‐cell survival and preserving capacity of insulin secretion in patients with diabetes mellitus.
- 28 June 2008
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 10 (7) , 564-573
Pioglitazone attenuates fatty acid–induced oxidative stress and apoptosis in pancreatic β‐cells
Aims: Thiazolidinediones (TZDs), ligands for peroxisome proliferator–activated receptor γ, are antidiabetic agents that improve hyperglycemia by decreasing insulin resistance in obese diabetic animal models and patients with type 2 diabetes. We have studied whether pioglitazone, a TZD, can exert a direct effect against pancreatic β‐cell lipoapoptosis. Methods: MIN6 cells were cultured in medium containing either 5.6 (low glucose) or 25 mM glucose (high glucose) in the presence or absence of 0.5 mM palmitate for 48 h. We examined the effect of 10 μM pioglitazone on MIN6 cells on glucose‐stimulated insulin secretion, cellular ATP, uncoupling protein‐2 (UCP‐2) mRNA expression, intracellular triglyceride content, reactive oxygen species production, the number of apoptotic cells and nuclear factor‐κB (NF‐κB) activity. Results: Pioglitazone recovered partly impaired glucose‐stimulated insulin secretion and cellular ATP in MIN6 cell exposed to high glucose with 0.5 mM palmitate. Pioglitazone suppressed intracellular triglyceride accumulation in cells exposed to high glucose with 0.5 mM palmitate. Palmitate‐induced upregulation of UCP‐2 mRNA levels was suppressed by pioglitazone in a dose‐dependent manner. Pioglitazone decreased palmitate‐induced reactive oxygen species production in MIN6 cells by 24% and in mouse islet cells by 53%. Pioglitazone also decreased palmitate‐induced NF‐κB activity by 40% and protected β‐cells from palmitate‐induced apoptosis by 22% in MIN6 cell. Conclusions: Pioglitazone attenuated fatty acid–induced oxidative stress and apoptosis in pancreatic β‐cells. TZDs might be used as a mean for maintaining β‐cell survival and preserving capacity of insulin secretion in patients with diabetes mellitus.
- 30 September 2007
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 77 (3) , 351-356
Oral pioglitazone administration increases food intake through ghrelin-independent pathway in Zucker fatty rat
- 30 September 2007
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 77 (3) , 351-356
Oral pioglitazone administration increases food intake through ghrelin-independent pathway in Zucker fatty rat